University of California Berkeley seal E. O. Lawrence Berkeley National Laboratory seal
The Carcinogenic Potency Project

Methyleugenol (CAS 93-15-2)
SMILES, InChI and Structure are below.
Rats and Mice: Cancer Test Summary
Rat Target Sites Mouse Target Sites TD50 (mg/kg/day)
Male Female Male Female Rat Mouse
kid liv mgl per sto sub liv sto liv sto liv 19.7m 19.3m

Key to the Table Above

Positivity: For each chemical with a positive (carcinogenic) experiment in the Carcinogenic Potency Database (CPDB), results are included on carcinogenic potency (TD50) in each species and target sites in males and females. Positivity is determined by an author’s opinion in a published paper. If all experimental results in the CDPB are negative in a sex-species group, “no positive” appears. If the CPDB has no experiments in the sex-species group, “no test” appears. The summary presents the strongest evidence of carcinogenicity in each group. If there are both positive and negative experiments in a sex-species, the negative results are ignored in this Summary Table.
Target Site Codes:   kid = kidney. liv = liver. mgl = mammary gland. per = peritoneal cavity. sto = stomach. sub = subcutaneous tissue. Target sites are listed if any author of published experimental results concluded that tumors were induced in that organ by the test agent. If there is more than one positive experiment in a sex-species, target sites listed may be from more than one experiment, e.g. if liver and lung are both listed, then liver may have been a target in one experiment and lung in another.
TD50: Our standardized measure of carcinogenic potency, TD50, is the daily dose rate in mg/kg body weight/day to induce tumors in half of test animals that would have remained tumor-free at zero dose. Whenever there is more than one positive experiment in a species, the reported TD50 value is a Harmonic Mean calculated using the TD50 value from the most potent target site in each positive experiment.
Superscripts:   m = There is more than one positive experiment in the species, and TD50 values from each positive experiment are used in the calculation of the reported Harmonic mean of TD50.

The Carcinogenic Potency Database (CPDB) is a unique and widely used international resource of the results of 6540 chronic, long-term animal cancer tests on 1547 chemicals. The CPDB provides easy access to the bioassay literature, with qualitative and quantitative analyses of both positive and negative experiments that have been published over the past 50 years in the general literature through 2001 and by the National Cancer Institute/National Toxicology Program through 2004. The CPDB standardizes the diverse literature of cancer bioassays that vary widely in protocol, histopathological examination and nomenclature, and in the published author’s choices of what information to provide in their papers. Results are reported in the CPDB for tests in rats, mice, hamsters, dogs, and nonhuman primates.

For each experiment, information is included on species, strain, and sex of test animal; features of experimental protocol such as route of administration, duration of dosing, dose level(s) in mg/kg body weight/day, and duration of experiment; experimental results are provided on target organ, tumor type, and tumor incidence; carcinogenic potency (TD50) and its statistical significance; shape of the dose-response, author’s opinion as to carcinogenicity, and literature citation.

Only tests with dosing for at least ¼ the standard lifespan of the species and experiment length at least ½ the lifespan are included in the CPDB. Only routes of administration with whole body exposure are included. Doses are standardized, average dose rates in mg/kg/day. A description of methods used in the CPDB to standardize the diverse literature of animal cancer tests is presented for: 1) Criteria for inclusion of experiments 2) Standardization of average daily dose levels and 3) TD50 estimation for a standard lifespan. See Methods for other details.

TD50 provides a standardized quantitative measure that can be used for comparisons and analyses of many issues in carcinogenesis. The range of TD50 values across chemicals that are rodent carcinogens is more than 100 million-fold. More than half the chemicals tested are positive in at least one experiment.

A plot of all results on each experiment in the CPDB for this chemical is presented below. These results are the source information for the Cancer Test Summary table above.

Methyleugenol: All Experiments and Citations in CPDB

The definition of each code in the plot below will appear in a pop-up window when the field name in the header line is clicked, e.g., Strain, Site, Path. Each numbered line starts a new experiment and reports protocol information in black. Average daily dose-rates per kg body weight per day are in green. Remaining lines report experimental results in blue.

Abbreviations of fields in header line: # = the line number in the plot of all CPDB chemicals; Xpo = duration of dosing; Xpt = duration of experiment; Site = tissue; Path = tumor type; DR = dose-response; AuOp = author’s opinion about carcinogenicity; LoConf, UpConf = confidence limits (99%) on TD50; Inc = tumor incidence for each dose group.

See Guide to reading the plot for details on each field, using an example of one experiment.

See Help to improve readability, or to fit the plot onto the screen or a printed page.



Chemical (Synonym) CAS
# Species Sex Strain Route Xpo+Xpt PaperNum        0 Dose  1 Dose 2 Dose  3 Dose          Literature Reference or NCI/NTP:Site Path
Site Path Notes   TD50  DR Pval    AuOp LoConf UpConf   Cntrl   1 Inc  2 Inc   3 Inc                                                        Brkly Code

METHYLEUGENOL 93-15-2 3954 M f b6c gav 24m24 TR491 : 0 26.4mg 53.6mg 107.mg liv MXA 14.6mg * P<.0005 10.5mg 21.7mg 7/50 38/50 48/50 49/50 liv:hpb,hpc. S liv hpc 14.9mg * P<.0005 c 10.7mg 22.4mg 7/50 37/50 47/50 47/50 liv MXA 15.9mg Z P<.0005 c 10.6mg 27.7mg 25/50 50/50 49/50 49/50 liv:hpa,hpb,hpc. liv MXA 15.9mg Z P<.0005 c 10.6mg 27.7mg 25/50 50/50 49/50 49/50 liv:hpa,hpc. liv MXB 15.9mg Z P<.0005 10.6mg 27.7mg 25/50 50/50 49/50 49/50 liv:hcc,hpa,hpb,hpc. C liv MXA 15.9mg Z P<.0005 10.6mg 27.7mg 25/50 50/50 49/50 49/50 liv:hpa,hpb,hpc. S liv hpa 18.2mg Z P<.0005 c 11.9mg 32.7mg 20/50 48/50 46/50 41/50 liv hpb 54.1mg * P<.0005 c 33.2mg 93.6mg 0/50 6/50 11/50 15/50 sub fbs 89.7mg Z P<.004 32.2mg 611.mg 0/50 5/50 (1/50 0/50) S liv hcc 1.62gm * P<.05 c 399.mg n.s.s. 0/50 0/50 0/50 2/50 TBA MXB 21.2mg * P<.0005 13.0mg 45.4mg 41/50 50/50 49/50 49/50 liv MXB 15.9mg Z P<.0005 10.6mg 27.7mg 25/50 50/50 49/50 49/50 liv:hpa,hpb,hpc. lun MXB no dre P=1. 298.mg n.s.s. 7/50 4/50 1/50 2/50 lun:a/a,a/c. 3955 M m b6c gav 24m24 TR491 : 0 26.4mg 53.6mg 107.mg liv hpa C 24.7mg Z P<.04 10.3mg n.s.s. 26/50 43/50 (38/50 39/50) S liv MXA C 27.3mg Z P<.07 c 10.6mg n.s.s. 31/50 47/50 (46/50 40/50) liv:hpa,hpc. liv MXB C 27.3mg Z P<.07 10.6mg n.s.s. 31/50 47/50 (46/50 41/50) liv:hpa,hpb,hpc. C MXB MXB C 27.3mg Z P<.07 10.6mg n.s.s. 31/50 47/50 (46/50 41/50) liv:hpa,hpb,hpc; stg:nem. M liv hpb C 1.28gm * P<.03 c 438.mg n.s.s. 0/50 0/50 1/50 3/50 stg nem C 2.30gm * P<.07 p 566.mg n.s.s. 0/50 0/50 0/50 2/50 TBA MXB 338.mg * P<.6 55.3mg n.s.s. 41/50 48/50 49/50 45/50 liv MXB C 27.3mg Z P<.07 10.6mg n.s.s. 31/50 47/50 (46/50 41/50) liv:hpa,hpb,hpc. lun MXB 275.mg * P<.2 93.4mg n.s.s. 15/50 13/50 25/50 20/50 lun:a/a,a/c. 3956 R f f34 gav 24m24 TR491 : 0 26.4mg 53.6mg 107.mg MXB MXB C 25.2mg Z P<.0005 18.4mg 36.1mg 1/50 9/50 29/50 44/50 liv:hpa,hpc; stg:neb,nem. C stg MXA C 34.3mg Z P<.0005 c 24.3mg 50.0mg 0/50 1/50 25/50 34/50 stg:neb,nem. liv MXA C 40.3mg Z P<.0005 c 27.7mg 63.2mg 1/50 8/50 14/50 34/50 liv:hpa,hpc. liv hpa C 44.2mg Z P<.0005 c 30.1mg 70.9mg 1/50 8/50 11/50 33/50 stg nem C 54.8mg Z P<.0005 c 36.3mg 87.2mg 0/50 1/50 12/50 26/50 stg neb C 100.mg Z P<.0005 c 52.4mg 233.mg 0/50 0/50 13/50 (9/50) liv hpc C 197.mg * P<.0005 c 97.7mg 489.mg 0/50 0/50 4/50 8/50 for MXA 557.mg * P<.02 e 188.mg 93.5gm 0/50 0/50 1/50 3/50 for:sqc,sqp. liv MXA C 852.mg * P<.02 237.mg n.s.s. 0/50 0/50 0/50 3/50 liv:hcc,hch. S TBA MXB 67.1mg * P<.06 27.0mg n.s.s. 47/50 49/50 48/50 47/50 liv MXB C 40.3mg Z P<.0005 27.7mg 63.2mg 1/50 8/50 14/50 34/50 liv:hpa,hpb,hpc. 3957 R f f34 gav 12m24 TR491a : 0 109.mg liv hpa C 25.5mg P<.0005 c 16.4mg 42.9mg 1/50 43/50 liv MXA C 25.5mg P<.0005 c 16.4mg 42.9mg 1/50 43/50 liv:hpa,hpc. stg MXA C 25.5mg P<.0005 c 16.4mg 41.7mg 0/50 41/50 stg:neb,nem. MXB MXB C 25.5mg P<.0005 16.4mg 42.9mg 1/50 43/50 liv:hcc,hch,hpa,hpc; stg:neb,nem. C stg nem C 26.9mg P<.0005 c 16.9mg 45.1mg 0/50 36/50 liv hpc C 63.8mg P<.0005 c 36.6mg 120.mg 0/50 22/50 liv MXA C 86.4mg P<.0005 c 46.8mg 176.mg 0/50 17/50 liv:hcc,hch. liv hcc C 171.mg P<.0005 c 77.5mg 503.mg 0/50 9/50 liv hch C 199.mg P<.0005 c 85.0mg 673.mg 0/50 8/50 stg neb C 528.mg P<.009 c 197.mg 12.3gm 0/50 5/50 amd pob 262.mg P<.03 92.1mg n.s.s. 1/50 6/50 S TBA MXB 152.mg P<.4 35.6mg n.s.s. 47/50 47/50 liv MXB C 25.5mg P<.0005 16.4mg 42.9mg 1/50 43/50 liv:hpa,hpb,hpc. 3958 R m f34 gav 24m24 TR491 : 0 26.4mg 53.6mg 107.mg MXB MXB 14.1mg Z P<.0005 9.63mg 22.1mg 12/50 28/50 39/50 47/50 ---:msm; liv:hcc,hch,hpa,hpc; mgl:fba; stg:neb, nem; sub:fbs,fib. C liv MXA 21.1mg Z P<.0005 c 14.4mg 32.8mg 7/50 14/50 28/50 43/50 liv:hpa,hpc. liv hpa 24.6mg Z P<.0005 c 16.6mg 38.8mg 5/50 12/50 23/50 38/50 liv hpc 45.2mg Z P<.0005 c 27.8mg 78.8mg 2/50 3/50 14/50 25/50 mgl MXA 46.9mg Z P<.0005 26.0mg 109.mg 5/50 5/50 16/50 13/50 mgl:ade,car,fba. S mgl fba 50.6mg * P<.0005 c 27.8mg 121.mg 5/50 5/50 15/50 13/50 sub MXA 59.1mg Z P<.0005 32.3mg 174.mg 1/50 13/50 8/50 8/50 sub:fbs,fib,fih. S sub MXA 60.1mg * P<.0005 c 32.7mg 173.mg 1/50 12/50 8/50 8/50 sub:fbs,fib. sub fib 79.7mg * P<.002 c 40.0mg 351.mg 1/50 9/50 8/50 5/50 kid MXA 110.mg Z P<.002 49.2mg 544.mg 3/50 2/50 6/50 6/50 kid:rab,rua. S kid MXA 115.mg Z P<.003 49.4mg 808.mg 4/50 2/50 6/50 6/50 kid:rab,rua,ruc. S --- msm 172.mg * P<.0005 c 85.8mg 469.mg 1/50 3/50 5/50 12/50 stg MXA 352.mg Z P<.0005 c 143.mg 1.14gm 0/50 0/50 0/50 7/50 stg:neb,nem. stg nem 520.mg Z P<.003 169.mg 3.58gm 0/50 0/50 0/50 4/50 S stg neb 1.11gm * P<.02 334.mg n.s.s. 0/50 0/50 0/50 3/50 S liv MXA 1.64gm * P<.05 c 488.mg n.s.s. 0/50 0/50 1/50 2/50 liv:hcc,hch. liv hcc 2.80gm * P<.2 685.mg n.s.s. 0/50 0/50 1/50 1/50 liv hch 3.97gm * P<.2 647.mg n.s.s. 0/50 0/50 0/50 1/50 TBA MXB 19.1mg Z P<.0005 11.4mg 43.0mg 48/50 48/50 48/50 49/50 liv MXB 21.1mg Z P<.0005 14.4mg 32.8mg 7/50 14/50 28/50 43/50 liv:hpa,hpb,hpc. 3959 R m f34 gav 24m24 TR491 with step 0 26.4mg 53.6mg 107.mg kid MXA 237.mg * P<.004 124.mg 1.95gm 4/50 6/50 17/50 13/50 kid:rab,rua. S kid MXA 263.mg * P<.01 c 130.mg 15.1gm 5/50 6/50 17/50 13/50 kid:rab,rua,ruc. 3960 R m f34 gav 53w97 TR491a : 0 116.mg liv MXA 11.4mg P<.0005 c 5.53mg 23.7mg 7/50 45/50 liv:hpa,hpc. MXB MXB 11.7mg P<.0005 5.77mg 24.4mg 9/50 45/50 ---:msm; liv:hcc,hch,hpa,hpc; stg:neb,nem; sub:fib. C liv hpc 15.8mg P<.0005 c 6.89mg 34.2mg 2/50 36/50 liv hpa 16.7mg P<.0005 c 8.00mg 36.8mg 5/50 32/50 kid MXA 27.2mg P<.0005 8.27mg 138.mg 4/50 8/50 kid:rua,ruc. S kid rua 27.3mg P<.0005 8.21mg 137.mg 3/50 8/50 S stg MXA 33.6mg P<.0005 c 8.47mg 430.mg 0/50 4/50 stg:neb,nem. liv MXA 54.0mg P<.0005 c 15.6mg 155.mg 0/50 13/50 liv:hcc,hch. liv hcc 65.2mg P<.0005 c 16.2mg 298.mg 0/50 7/50 mgl fba 86.3mg P<.007 23.0mg 2.44gm 5/50 6/50 S stg neb 98.7mg P<.007 16.8mg 1.64gm 0/50 2/50 S stg nem 100.mg P<.008 16.9mg 2.04gm 0/50 2/50 S sub fib 164.mg P<.009 c 30.6mg 9.96gm 1/50 4/50 liv hch 313.mg P<.002 c 124.mg 1.27gm 0/50 6/50 --- msm 364.mg P<.02 c 127.mg n.s.s. 1/50 5/50 TBA MXB 9.61mg P<.0005 5.11mg 21.0mg 48/50 46/50 liv MXB 11.4mg P<.0005 5.53mg 23.7mg 7/50 45/50 liv:hpa,hpb,hpc. 3961 R m f34 gav 53w97 TR491a with step 0 116.mg kid rua 162.mg P<.0005 86.7mg 485.mg 4/50 20/50 S kid MXA 171.mg P<.0005 c 88.8mg 620.mg 5/50 20/50 kid:rua,ruc.

Mutagenicity in Salmonella: negative
SMILES Code for Methyleugenol: COc1cc(ccc1OC)CC=C
InChI Code for Methyleugenol: InChI=1/C11H14O2/c1-4-5-9-6-7-10(12-2)11(8-9)13-3/h4,6-8H,1,5H2,2-3H3
Source for SMILES and InChI: USEPA Distributed Structure-Searchable Toxicity (DSSTox) Database
Chemical Structure for Methyleugenol: Chemical Structure
Source for structure: National Library of Medicine ChemIDPlus

See full CPDB Summary Table on 1547 chemicals. See Full CPDB for all results on 6540 experiments of 1547 chemicals.

A complete list of CPDB chemicals, which is searchable by name or by CAS number, is available here.

For a compendium of CPDB results organized by target organ, which lists all chemicals in each species that induced tumors in each of 35 organs, see Summary Table by Target Organ.

The CPDB is available in several formats that permit printing and downloading into spreadsheets and statistical databases.

  1. A plot of the CPDB presents results of 1547 experiments on 6540 chemicals in an easily readable format that has been used in publications of the CPDB.
  2. A Screen version plot for use on a single computer screen, with the same data.
  3. Excel version of the same data.
  4. Tab-separated versions of the same data, which can be easily read into databases.

A Supplementary Dataset gives details on dosing and survival for each experiment.

Relatively precise estimates of the lower confidence limit on the TD10 (LTD10) are readily calculated from the TD50 and its lower confidence limit, which are reported in the CPDB. For researchers and regulatory agencies interested in LTD10 values, we provide them in an Excel spreadsheet.

PDF versions of our publications of analyses using the CPDB are available, organized by year and by research topic.


Carcinogenic Potency Database Project (CPDB) Home Page
For more information about this Web Page, contact Specialized Information Services (tehip@teh.nlm.nih.gov).
Last updated: October 3, 2007


PDF documents are best viewed with the free Adobe® Reader http://get.adobe.com/reader
Excel documents are best viewed with the free Excel® Viewer http://www.microsoft.com/en-us/download/details.aspx?id=10